Remove Academic Remove Outcomes Remove Stent
article thumbnail

SMT Publishes Trial Results for Supraflex Cruz Stent

DAIC

Smits and a distinguished team of international researchers, the trial compares the performance of SMT's biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the biodegradable-polymer Ultimaster Tansei * stent in patients with high bleeding risk (HBR) undergoing abbreviated dual antiplatelet therapy (DAPT).

Stent 52
article thumbnail

Top Specialties in Fellowship Programs and What They Offer: An In-depth Look for Medical Professionals

ADN Center of Excellence

Our Interventional Cardiology Fellowship Program offers a unique opportunity for fellows to immerse themselves in high-volume centers and experience complex procedures such as angioplasties, stent placements, and Chronic Total Occlusion (CTO) interventions.

Cancer 59
article thumbnail

Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial

Circulation

BACKGROUND:In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. points (P=0.36), respectively.

article thumbnail

An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial

Circulation

There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point. 3.30]) and subacute definite or probable stent thrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26–9.23]) mg/day) monotherapy or to DAPT with aspirin (81–100 mg/day) and prasugrel (3.75

Stent 40
article thumbnail

Outcomes of ticagrelor versus high dose clopidogrel in CYP2C19 intermediate metabolizer undergoing percutaneous coronary intervention for acute coronary syndromes

Journal of Cardiovascular Pharmacology

Patient characteristics and clinical outcomes were collected via electronic medical record system. The primary outcome was major adverse cardiac and cerebrovascular event (MACCE), namely a composite of death from cardiovascular causes, myocardial infarction (MI), stroke, stent thrombosis within 12 month.

article thumbnail

National Cardiogenic Shock Initiative Study Results Show Significant Increase in Heart Attack Survival

DAIC

have also prompted the use of our protocol in Japan where they are experiencing similar great outcomes.” Doctors then treat the cause of the heart attack, either inserting a stent, removing a clot or taking other necessary action. The impressive results from our study in the U.S. Division Head of Cardiology at Henry Ford Health.

article thumbnail

Modified percutaneous coronary intervention-derived risk models (PARIS and CREDO-Kyoto integer scoring systems) applied to Japanese transcatheter aortic valve replacement patients

Open Heart

Bleeding events were defined as any bleeding based on the Valve Academic Research Consortium-2 consensus document at 1 year. Patterns of Non-adherence to Anti-Platelet Regimen in Stented Patients (PARIS) and Coronary Revascularisation Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) integer scoring systems were tested.